| Background:The gastric cancer is one of the most common malignancies,the higher incidence and mortality of this cancer seriously threaten humanhealth and life. Surgical resection is still the preferred method of curing gastriccancer. But due to a variety of reasons, gastric cancer advanced treatmentmainly focus on Palliative surgery, radiation therapy, and medical treatment,which aims to alleviate the symptoms, improve the quality of life, controltumor growth and extend a patient’s survival time. So choosing the best gastriccancer treatment is especially important.In recent decades, scholars have donelots of clinical experimental study on gastric cancer advanced treatment, butthere is no gold standard till now. In recent years many study explores thecombination treatment of advanced gastric cancer by using the oral drugs suchas fluorouracil class capecitabine and platinum class and three types of taxoldrug, which gets good curative effect, extends the patients’ life time. At present,Capecitabine Combined with Cisplatin has become a basic program forfirst-line treatment of advanced gastric cancer,but paclitaxel joint capecitabineprogram is still a lack of high-level evidence based medicine in theinternational.Now a maintenance treatment of paclitaxel joint capecitabinesequential capecitabine, compair capecitabine cisplatin with the therapy whichcan’t surgery locally (recurrence or metastatic) of grastic cancer randomized,controlled, open, more phase III clinical research is on, this article is to thisstudy, the center assumes the parts of a tentative summary, the research provideresults for clinical evidence.Objective:Contrasting paclitaxel joint capecitabine sequentialcapecitabine (the experimental group) and capecitabine joint cisplatin(control group) which can’t surgery locally adanced/metastatic gastric cancer’srecurrence of the effect and side-effect.Methods:We make an analysis of30patients who received the treatmentof Paclitaxel joint capecitabine sequential capecitabine from April,2010toDecember,2011in our cancer center. We will also make a study of the patientswho received the treatment of Capecitabine cisplatin and those patients withphase3cancer of stomach who couldn’t receive a local operation in anadvanced lesion We divided the30samples into experimental group(Paclitaxel+capecitabine sequential capecitabine group of16cases) and controlgroup(Cisplatin+capecitabine group of14cases) randomly by usingcomputers.Result:Followed up time ends on March15,2012, all patients experiencea follow-up time of13months (3.0-23months), a median follow-up time trial13months (3.0-23months), in the control group, a follow-up time11.5months(6.0-17months). No lost to follow-up cases.16patients group, CR3example,PR4example, SD5example, PD4example, RR is43.75%,75.0%DCR. Thecontrol group14patients, CR2example, PR3example, SD4example, PD5example, RR is35.7%,64.3%DCR, two groups of RR, DCR has nostatistically significant.30patients were followed to on March15,2012,11cases of death trial,5cases of live, and the control group9cases died,5casesof live, and median PFS and median OS were6.0months and3.0months and9.0months and8.0months. In side reactions, two groups except alopecia hasno statistically significant.Conclusions:(1) in terms of efficacy, the experimental group comparedwith the control group, short-term effect is similar,for the long-term efficacy,the PFS improved, there are significant differences.(2) the toxicity of theexperimental group compared with the control group, in addition to hair loss,the incidence was no significant difference, good security, good patient tolerance.(3)Significant effect of paclitaxel plus capecitabine program can beused as advanced gastric cancer first-line treatment standards program. |
PDF Full Text Request